• :::Home
  • HK Technologies
  • Artificial Intelligence (AI) and Electrocephalogram (EEG)-based Drug's Screening  Platform

Artificial Intelligence (AI) and Electrocephalogram (EEG)-based Drug's Screening  Platform

logo-coloured-2019
Overview

CityU developed the AI and EEG based drug’s screening platform to facilitate the drug-screening process of investigational new drugs, predict the potential activity, pharmacological targets and toxicity. It helps to identify the most promising compounds with efficient manner, resulting in saving of cost and time and accelerate the drug development process.

  • Artificial Intelligence (AI) and Electrocephalogram (EEG)-based Drug's Screening  Platform 0
  • Artificial Intelligence (AI) and Electrocephalogram (EEG)-based Drug's Screening  Platform 1
Technical name of innovation
Smart drug discovery platform
Research completion
2022
Commercialisation opportunities
Technology licensing agreement has been signed with a City University of Hong Kong start-up
Problem addressed

The process of developing a novel drug is time consuming and costly. Merely a small fraction of investigational new drugs tested in clinical trials after passing preclinical evaluation eventually lead to a marketed product. Hence, Our AI platform offer an opportunity to overcome these obstacles and enhance the success rate of drug development to enter in the market.

Innovation
  • Artificial intelligence (AI) and machine learning (ML) based encephalogram (EEG) platform
  • Translational prediction of mice model disease to human disease
  • Online portal will show the results of the study in real-time.
Key impact
  • Our AI platform will reduce drug's screening time by 50% and results will be available in real-time.
  • It will narrow down the potent molecule and help to increase the change of successful clinical trial.
  • In the following step of drug development, pharmaceutical company could omit investigating on hit and trial method.
  • It will aid to exiting regulatory requirement of FDA or NMPA and fasten the process of drug discovery.
Award
  • Gold Medal at at Invention Geneva Evaluation Days 2021
  • Hong Kong SciTech Pioneers Award (2021)
  • City Univesity of Hong Kong; Hong Kong Tech 300, Seed Fund (HKD $1,000,000)
  • City Univesity of Hong Kong; Hong Kong Tech 300 Angel Fund (HKD $1 million); 2022
  • City Univesity of Hong Kong; Technology Start-up Support Scheme for University (TSSSU) Fund (HKD $670,000); 2022
Application
  • Our platform will be utilised by pre-clinical contract research organisations (CROs), pharmaceuticals, medical devices, supplementary health products, chemicals, agrochemicals, and biocides.
  • The invented Artificial intelligence and machine learning model will predicts the translational probability of symptoms from pre-clinical to clinical disease condition.
  • Food and Drug Administration (FDA, USA) and National Medical Products Administration (NMPA, China) will utilise our platform to access the data raw data the real-time to fasten drugs approval.
  • Our platform will be accessed by all the drugs development industry. Due to online availability of the study in real-time, it will prevent the duplication of study across the globe.

Patent

  • US patent application no. 63/243,749, filed on 14 Sep 2021 (CityU IDF no. 1031)
City University of Hong Kong (CityU)

As one of the fastest growing universities in the world over the past decade, City University of Hong Kong (CityU) is recognised as a hub for innovation in research and professional education. CityU identifies solutions to critical global challenges by extending the frontiers of knowledge both within and beyond existing research paradigms.

The University’s highly qualified academics are drawn from all over the world, not only bringing a wealth of research and professional experience to the teaching programmes, but also contributing to the knowledge and technology advancement.

Enquiry
Related Innovations